Shu Chin Ma has been in the pharmaceutical industry since 2004. She has worked as a senior scientist and a project leader for biotech companies developing siRNA transfection technologies and synthetic antibodies for immunosuppresion. She also taught health sciences in academic institution. Prior to joining Certara she worked in a dual role of a primary drug application reviewer and interdisciplinary scientist for the FDA for 3 years. Shu Chin’s areas of interest include Parkinson’s disease, pediatric dosing, the Animal Rule and the development of nanoparticles as gene and drug transport vehicles. She has extensive practical experience in in vitro and in vivo experimentations.
Shu Chin received her Bachelor of Engineering in Chemicals and Materials Engineering (1st class honors) from the University of Auckland, New Zealand, her MSc in Biomedical Engineering with minors in Neurosciences and Materials Science from Cornell University (Ithaca, NY), and her MPhil and PhD in Biomedical Engineering from Yale University (New Haven, CT). She completed her postdoc at the Center for Brain Research at the University of Auckland and worked as research assistant in Prof. Nick Holford’s lab.